QED Therapeutics Stock

A biotechnology company focused on precision medicine for FGFR-driven disorders.

About QED Therapeutics Stock

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

Funding History

January 2018	$65.0M

Management

President

Neil Kumar

CRO

Curtis Scribner

Other Companies

Learn More

Akili Interactive Labs

Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games.

$128MTotal Funding

Learn More

Bayer

Multinational pharmaceutical and life sciences company

$3.0BTotal Funding

Learn More

Green Growth Brands

Green Growth Brands is a lifestyle oriented, consumer products company that celebrates health, wellness and happiness

$85.0MTotal Funding

Learn More

Theragene Pharmaceuticals

Theragene Pharmaceuticals combines innovative science and efficiency to develop life-saving therapies for many debilitating diseases.

$548KTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from QED Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 80K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.